Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.’s Net Profit Rose 144.5% in First Three Quarters of 2023

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (上海复旦张江生物医药股份有限公司) (688505.SH) reported a net profit of 89.8 million yuan in the first three quarters of 2023, up 144.5% year-on-year.

Meanwhile, the company posted 708 million yuan in revenue, down 1.2% year-on-year.

At the end of the reporting period, it had 2.9 billion yuan in total assets and 609.2 million yuan in total liabilities, with a liability-to-asset ratio of 20.7%.